Clinical Trials Logo

Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue clinical trials

View clinical trials related to Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.

Filter by:
  • None
  • Page 1

NCT ID: NCT02339922 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Start date: May 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ixazomib citrate and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that grows slowly (indolent). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate together with rituximab may work better in treating indolent B-cell non-Hodgkin lymphoma.

NCT ID: NCT02332980 Recruiting - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Start date: February 19, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement or have not responded to treatment. Monoclonal antibodies, such as pembrolizumab, block cancer growth in different ways by targeting certain cells and allow the immune system to attack the cancer. Idelalisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab alone or with idelalisib or ibrutinib may be an effective treatment in patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas.